On August 4, 2016, Lance Thibault notified the Proteostasis Therapeutics, Inc. of his resignation from his position as Principal Financial Officer and Principal Accounting Officer, effective as of August 4, 2016. On July 14, 2016, the Board elected James M. DeTore, the Company’s Chief Financial Officer, as the Company’s Treasurer and as Company’s Principal Financial Officer conditioned upon and effective as of the effective date of Mr. Thibault’s resignation. On July 14, 2016, the Board also elected Brett R. Hagen, the Company’s Controller, as the Company’s Principal Accounting Officer conditioned upon and effective as of the date of Mr. Thibault’s resignation. Mr. DeTore, 51, served as Chief Financial Officer and Treasurer of bluebird bio since November 2014. Prior to joining bluebird, Mr. DeTore served as Vice President, Corporate Finance of Ironwood Pharmaceuticals, Inc. from February 2010 to November 2014, as Vice President, Finance from June 2006 to January 2010 and as Corporate Controller of Microbia, Inc. (Ironwood’s predecessor company) from October 2003 to May 2006. From May 1995 through September 2003, Mr. DeTore held financial positions of increasing responsibility at Genzyme Corporation. Mr. Hagen, 43, has been serving as the Company’s Controller since May 2016. Previously, Mr. Hagen served as a controller for BIND Therapeutics, Inc., Vice President, Finance/Segment Controller of Boston Private Financial Holdings, Manager of SEC Financial Reporting and Technical Account of The Princeton Review, Controller of BioProcessors Corporation and held a number of positions at PricewaterhouseCoopers LLP. He received a B.A. from University of Minnesota, a Master in Accountancy from Wright State University and a M.S. in Finance from Suffolk University. On August 3, 2016, Conor Walshe notified the Company of his resignation from the Company’s Board and from his position as member of the Audit Committee, effective as of August 1, 2016. On August 3, 2016, the Board elected Eric Rabinowitz to serve as a director and member of the Audit Committee, effective as of August 3, 2016. Mr. Rabinowitz, 40, has served as Vice President of Corporate Development at Perrigo Company, plc since August 2014. Prior to Perrigo, Mr. Rabinowitz held several positions of increasing responsibility in Barclays Capital, Inc. from June 2010 to August 2014 including Vice President of Investment Banking, Health Care Mergers & Acquisitions, Director of Investment Banking, Health Care Mergers & Acquisitions, and Managing Director of Investment Banking, Health Care Mergers & Acquisitions. From February 2009 to May 2010 he served as Director, Investment Banking, Health Care Group and as Executive Director, Investment Banking, Health Care group at Oppenheimer & Co. Inc.